Healis Therapeutics has entered into a supply agreement with CKD Bio Corporation, a subsidiary of Chong Kun Dang group, for CKDB-501, a neuromodulator BoNT/A protein.

Healis Therapeutics intends to develop CKDB-501 for major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). In addition, Healis plans to enter clinical trials in the U.S. and other countries.

According to Healis, ten randomized controlled trials conducted in five countries to date have shown promising early results on glabellar Botulinum Toxin Type A (BoNT/A) treatments for Major Depressive Disorder (MDD).

“We are excited to work with CKD Bio, a global leader in biologics, on a collaboration to develop CKDB-501 for MDD and PTSD,” said Eric Finzi, co-Founder of Healis. “We hope this partnership will accelerate the development of BoNT/A as a potential on-label treatment available to millions of MDD and PTSD patients worldwide.”

Sebastian De Beurs, co-Founder of Healis said, “Our collaboration with CKD Bio on this new agreement could one day impact over 42 million Americans. This planned clinical development represents the largest patient population and market opportunity of any therapeutic indication in the history of BoNT/A.”